ESR1 and breast cancer: Treatment of the cells with the ERα-specific antagonist 4-hydroxytamoxifen (4-OHT) reversed the E2-reduced expression of the same genes (Figure 3A), indicating the importance of ERα in mediating the effect of E2 on p53 transcriptional activity in ERα-positive breast cancer cells.